Recent articles have shed light on an issue of concern about counterfeits for patients who take imatinib myselate as part of their treatment for GIST.
Executive Director & Founder Norman J. Scherzer announced his retirement today after 20+ years of leading the Life Raft Group; former VP of Program Services Sara Rothschild has been appointed to Executive Director position supported by Deputy Executive Director Laura Occhiuzzi, and our experienced LRG staff.
The LRG welcomes three new members to its Board of Directors: Pat Bonda-Swenson, Santy DiSabatino and Bill Borwegen.
Holidays can be a challenge. There may be pressure to recreate a ‘Norman Rockwellesque’ experience with the perfect turkey and many happy, family photos in holiday-themed pajamas. Here are some tips to deal with the stress.
Fall is finally here, and with it comes the onset of Flu Season. Flu is a difficult illness for everyone, but for cancer patients, it can be devastating. It is especially confusing in this year which continues to challenge everyone with the uncertainty of COVID-19 and its variants.
COVID-19 - Resources GIST Patients Need - Please know that the Life Raft Group is here to support you during this Coronavirus crisis. We will continue our daily services during this time and we will be distributing information and messages of hope through all our communication channels.
Looking back to March 13, 2020, when we said goodbye to our normal work environment, being together, and when our world both personally and professionally changed radically.
For many, the holidays are challenging normally and for cancer patients, the expectations of a consistently happy mood may be unrealistic. If you are newly diagnosed, the realization of what treatment means is probably not yet fully absorbed.
Get Ready to Have Fun at the Women in Sarcoma Virtual Gala. Here are ways to up your fun and participate on this night when we honor the Women in Sarcoma award recipients.
Concerning Medicare Open Enrollment: It is especially important for GIST patients to carefully consider available plans, as one of the financial support resources that has been available through Novartis Pharmaceuticals will end on January 1, 2021.